Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ] - Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
[ Fri, Sep 03rd 2010 ] - Market Wire
Transdel Pharmaceuticals

The Briscoe Law Firm and Powers Taylor, LLP Investigate Possible Breaches of Fiduciary Duties by the Officers and Directors of


//health-fitness.news-articles.net/content/2010/ .. ary-duties-by-the-officers-and-directors-of.html
Published in Health and Fitness on Tuesday, September 14th 2010 at 8:05 GMT by Market Wire   Print publication without navigation


DALLAS--([ BUSINESS WIRE ])--[ The Briscoe Law Firm, PLLC ], founded by a former state prosecutor and enforcement attorney for the United States Securities and Exchange Commission, and the law firm of Powers Taylor, LLP are investigating potential legal claims available to purchasers of [ Acura Pharmaceuticals, Inc ]. (aACURa or aCompanya) (NASDAQ: ACUR) shares between February 21, 2006 and April 22, 2010.

It has been alleged that ACUR and certain of its officers and directors violated the Securities Exchange Act of 1934 by concealing information regarding the effectiveness of ACURa™S drug Acurox, an orally administered oxycodone immediate release tablet. Specifically, a recently filed federal complaint alleges that ACUR concealed material adverse facts about Acurox, including: (i) ACURa™s clinical trials were not properly designed to obtain FDA approval; (ii) ACUR did not have evidence that its niacin additive discouraged oxycodone abuse; and (iii) ACURa™s Aversion Technology was not effective enough to obtain FDA approval. The FDA voted 19 to 1 against approving Acurox, and after the FDA decision was fully reported to the market between April 20, 2010 and April 22, 2010, ACUR stock dropped nearly 50%. As a result of ACURa™s officersa™ and directorsa™ alleged concealment, ACURa™s stock traded at artificially inflated prices.

If you currently own or purchased Acura Pharmaceutical / ACUR shares and would like additional information regarding this investigation or if you have information regarding the allegations against ACUR, please contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at [ patrick@powerstaylor.com ], or Willie Briscoe at The Briscoe Law Firm, PLLC, toll free (877) 397-5991 or via email at [ WBriscoe@TheBriscoeLawFirm.com ]. There is no cost or fee to you.

The Briscoe Law Firm is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.


Publication Contributing Sources